Brentuximab 

Brentuximab is a monoclonal antibody targeting CD30. Brentuximab is conjugated with monomethyl auristatin E (MMAE) (HY-15162) to form the antibody-drug conjugate Brentuximab vedotin (HY-P99107), which can induce apoptosis in primary effusion lymphoma cells. Brentuximab vedotin exhibits antitumor activity with an IC₅₀ of 10 nM against human CD30+ cancer cells^[1][2][3].

Human IgG1 kappa

Human IgG1 kappa, Isotype Control

Chimeric

2088770-90-3

液体

Colorless to light yellow

Shipping with dry ice.

Please store the product under the recommended conditions in the Certificate of Analysis.

• 
  Human IgG1 kappa
• 
  Immobilized CD30/TNFRSF8 Protein, Human can bind Brentuximab. The EC₅₀ for this effect is 6.007 ng/mL.

• [1]. Bhatt S, et al. CD30 targeting with brentuximab vedotin: a novel therapeutic approach to primary effusion lymphoma. Blood. 2013 Aug 15;122(7):1233-42.  [Content Brief]

  [2]. Chen R W, et al. Inhibition of MDR1 overcomes brentuximab vedotin resistance in Hodgkin lymphoma cell line model and is synergistic with brentuximab vedotin in mouse xenograft model[J]. Blood, 2016, 128(22): 752.

  [3]. Wang Z, et al. CCR4-IL2 bispecific immunotoxin is more effective than brentuximab for targeted therapy of cutaneous T-cell lymphoma in a mouse CTCL model. FEBS Open Bio. 2023 Jul;13(7):1309-1319.  [Content Brief]